Peninsula biotech sheds half its value after deciding to continue multiple sclerosis study


It's not that the South San Francisco company's cell therapy doesn't work; it's just that this study couldn't make the statistical leap after six months of clinical trial data that it would work at 12 months.

Previous Martin Shkreli's onetime company loses 80% of value as Covid drug trial fails
Next Hamburger chain says it has out-of-the-box ambitions for Wichita